Clinical predictors of outcome in MPN

Francesco Passamonti; Margherita Maffioli; Michele Merli; Andrea Ferrario; Domenica Caramazza

doi:10.1016/j.hoc.2012.07.009

Clinical predictors of outcome in MPN

Hematol Oncol Clin North Am. 2012 Oct;26(5):1101-16. doi: 10.1016/j.hoc.2012.07.009. Epub 2012 Aug 28.

Authors

Francesco Passamonti¹, Margherita Maffioli, Michele Merli, Andrea Ferrario, Domenica Caramazza

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Viale Borri 57, 21100 Varese, Italy. [email protected]

PMID: 23009940
DOI: 10.1016/j.hoc.2012.07.009

Abstract

Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are dominated by a high risk of thrombosis and a late risk of clonal evolution into secondary MF and acute myeloid leukemia. Patients with PMF may encounter many complications associated with disease progression or with PMF evolution. This article defines factors that determine prognosis in these 3 diseases.

Publication types

Review

MeSH terms

Humans
Polycythemia Vera / etiology
Polycythemia Vera / mortality*
Polycythemia Vera / therapy
Primary Myelofibrosis / etiology
Primary Myelofibrosis / mortality*
Primary Myelofibrosis / therapy
Prognosis
Risk Factors
Survival Rate
Thrombocythemia, Essential / etiology
Thrombocythemia, Essential / mortality*
Thrombocythemia, Essential / therapy